Prot#R668-AD-0914: A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients with Moderate-to-Severe Extrinsic Atopic Dermatitis

Project: Research project

StatusFinished
Effective start/end date2/1/112/1/14

Funding

  • Ingenix Pharmaceutical Services, Inc. (R668-AD-0914)
  • Regeneron Pharmaceuticals, Inc. (R668-AD-0914)